Ashley Lakner, PhD, Head, Oncology Discovery - pRED Oncology, Roche, discusses the modalities they’re most interested in, their work moving beyond established checkpoint inhibitors and understanding immunogenicity, and the challenges in designing drugs for the patient of the future, amongst other topics.
Lead Editorial
